Frontiers in Cardiovascular Medicine (May 2023)
Corrigendum: Cost-effectiveness of adding empagliflozin to the standard therapy for Heart Failure with Preserved Ejection Fraction from the perspective of healthcare systems in China
Abstract
No abstracts available.Keywords